Clinical Trial Detail

NCT ID NCT02752074
Title A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

melanoma

Therapies

Epacadostat + Pembrolizumab

Pembrolizumab

Age Groups: adult

No variant requirements are available.